natgillin/translations-raw huggingface dataset:
The method of claim 24, wherein the disorders and diseases are selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
Spoj prema patentnom zahtjevu 10, naznačen time što je poremećaj ili bolest izabrana iz grupe koju čine poremećaji 1 bolesti srca, poremećaji i bolesti skeletnih mišića, kognitivni poremećaji, maligna hipertermija, dijabetes 1 sindrom iznenadne smrti novorođenčeta.
administering to the subject a composition comprising a therapeutically effective amount of soluble CD52 glycoprotein, wherein the soluble CD52 glycoprotein comprises the amino acid sequence of GQNDTSQTSSPS (SEQ ID NO: 3); and a pharmaceutical acceptable carrier. 
Topljivi glikoprotein CD52, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što topljivi glikoprotein CD52 sadrži aminokiselinski slijed GQNDTSQTSSPS (SEQ ID NO: 3) ili GQATTAASGTNKNSTSTKKTPLKS (SEQ ID NO: 5), te ugljikohidrat.
Pharmaceutical composition made of microparticles for the slow release of an LHRH agonist triptorelin, characterized in that said composition comprises a mixture of a first group of microparticles and a second group of microparticles, wherein 
Farmaceutski pripravak pripremljen od mikročestica za sporo oslobađanje LHRH agonista triptorelina, naznačeno time što taj pripravak sadrži prvu skupinu mikročestica i drugu skupinu mikročestica, gdje
and/or optionally followed by a second oxidation to obtain the following compound: 
: i zatim, prema potrebi, drugoj oksidaciji, čime se dobije slijedeći spoj:
the MSR further comprises: a baffle structure positioned in the vessel, between the heat exchangers and the graphite moderator core, the baffle structure to guide molten salt fluid flowing downwards in the vessel and out of the heat exchangers, along an outside periphery of the graphite moderator core; 
strukturu limenih vodilica smještenu u posudi između izmjenjivača topline i grafitne jezgre moderatora, koja struktura limenih vodilica služi vođenju fluida rastaljene soli prema dolje u posudi i izvan izmjenjivača topline duž vanjske periferije grafitne jezgre moderatora;
The compounds of formula (I) and salts and solvates thereof may be prepared by the methodology described hereinafter, constituting a further aspect of this invention. 
Spojeve formule (Ia), (Ib) 1 (Ic) 1 njihove soli i solvate može se dobiti metodologijom opisanom niže, što je daljnji aspekt ovog izuma.
The pharmaceutical composition of claim 11 wherein the therapeutic agent is amlodipine besylate. 
Farmaceutski sastav prema zahtjevu 13, naznačen time, da terapeutsko sredstvo je amlodipin besilat.
first sensing means (22) connected for signal communication with said monitoring and control unit (21) and suitable for detecting and acquiring at preset time intervals AT the value of a first pressure PT1 in said return circuit (14); 
prva osjetna sredstva (22) povezana radi signalne veze sa navedenom nadzornom i kontrolnom jedinicom (21) koja su pogodna za otkrivanje i dobivanje u unaprijed određenim vremenskim intervalima AT vrijednosti prvog tlaka PTI u navedenom povratnom krugu (14);
For instance, a compound of the formula VII may be converted into its corresponding Grignard reagent or lithium cuprate reagent and reacted with a compound of the formula VI. 
Na primjer, spoj formule VII može se prevesti u odgovarajući Grignardov reagens ili litij kuprat reagens 1 reagirati sa spojem formule VI.
The process of any one of claims 1 to 9, wherein the hydrogenation is carried out in a solvent, preferably in an alcohol, more preferably an alcohol selected from the group consisting of methanol, ethanol and isopropanol; or 
Postupak prema zahtjevu 6, gdje je otapalo odabrano iz skupine koja se sastoji od vode, izopropanola, metanola, etanola, te prikladne smjese dvaju ili više prethodno navedenih otapala.
In a preferred embodiment, 10 to 90%, preferably 30 to 85%, more preferably 60 to 80% by weight of the calcium carbonate material particles present, prior to treatment, a particle diameter of less than 1 um as measured according to the measurement method in the Examples section herebelow. 
Postupak prema bilo kojem od zahtjeva 1 ili 2, naznačen time da od 10 do 90 %, poželjno od 30 do 85 %, poželjnije od 60 do 80 % težinski čestica materijala koji sadrži kalcijev karbonat iz koraka a) ima promjer čestice od manje od 1 um.
The tube of claim 1 further comprising a jacket of one or more materials of a group consisting of polyethylene, ethylene chlorotrifluoroerthlyene, a thermoplastic elastomer cross linking ethylene propylene diene monomer rubber and polypropylene, perfluoroalkoxy, polyvinylidene fluoride and fluorinated ethylene propylene wherein the material is extruded onto the tube without radiation curing. 
Obložena cijev u skladu s patentnim zahtjevom 1, naznačena time što dodatno sadrži oblogu od jednog ili više materijala iz skupine koju čine polietilen, etilen-klortrifluoretilen, termoplastični elastomerni umreženi etilenpropilen-dien-monomer-kaučuk i polipropilen, perfluoralkoksi, poliviniliden-fluorid 1 fluorirani etilen-propilen, gdje se materijal ekstrudira na cijev bez stvrdnjavanja uz pomoć zračenja.
In one embodiment, the disclosure provides a compound of Formula I: 
PATENTNI ZAHTJEVI 1. = Spoj koji ima strukturu formule I:
is suitable for oral administration to a human; 
(i) pogodna za oralnu administraciju kod ljudi;
Package according to claim 1, characterised in that the lid comprises an edge wall, the hinge line of the lid being located at the edge wall. 
Omot za pakiranje u skladu s patentnim zahtjevom 1, naznačen time što poklopac ima stjenku brida, pri čemu se linija za preklapanje poklopca nalazi na stjenki brida.
The orthopedic screw of claim 2, wherein the plurality of facets are longitudinally cut into the leading or trailing edge of the thread. 
3. < Ortopedski vijak u skladu s patentnim zahtjevom 1, naznačen time što je više faceta uzdužno urezano u prednji ili stražnji rub navoja.
The compound, or a pharmaceutically acceptable salt thereof, of claim 6, wherein R21 is alkyl, a C1-C4 alkyl, cycloalkyl, or cycloalkylalkyl. 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 6, naznačen time, da je R21 alkil, C1-C4 alkil, cikloalkil ili cikloalkilalkil.
Method according to any [1] to [4], wherein the contacting step is carried out using 0,05 µmol of negatively charged phospholipids wherein the protein content of the microvesicles is lower than 50 microg and 0,1 µmol negatively charged phospholipids wherein the protein content of the microvesicles is higher than 50 microg. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 2, pri čemu se korak dovođenja u dodir provodi koristeći 0.05 umol negativno nabijenih fosfolipida pri čemu je sadržaj proteina u mikrovezikulama manji od 50 ug i 0.1 umola negativno nabijenih fosfolipida pri čemu je sadržaj proteina u mikrovezikulama veći od 50 ug.
from 0 wt% to 4 wt% of magnesium stearate, wt% designating an amount by weight, as a percentage of the total weight of the composition, 
od 0.5 tež% do 4 tež% magnezijevog stearata tež% označava količinu po težini, kao postotak ukupne težine pripravka.
positioning the frozen or deep-frozen food on a baking support in a raised (up-right position) position on said at least two support points, in the shape of an arch, and baking the food product whereby the concave surface of said food is facing the baking support; or positioning the frozen or deep-frozen food on a baking support on said multiple arch-shaped surface, the more than two support points contacting the baking support in an undulated manner; and baking the food product. 
(vi) postavljanje smrznutog ili duboko smrznutog prehrambenog proizvoda na nosač za pečenje u podignutom položaju (uspravnom položaju) na navedenim najmanje dvjema potpornim točkama, u obliku luka i pečenje prehrambenog proizvoda pri čemu je konkavna površina navedene hrane okrenuta prema nosaču za pečenje; ili postavljanje smrznutog ili duboko smrznutog prehrambenog proizvoda stranom sa višestrukim lukovima prema nosaču za pečenje, pri čemu više od dvije potporne točke dodiruju nosač za pečenje na valovit način; i pečenje prehrambenog proizvoda.
A method of treating non-insulin dependent diabetes mellitus, comprising administering to said mammal an effective amount of a compound of claim 1 . 
Uporaba spoja prema bilo kojem od zahtjeva 1-16 u proizvodnji lijeka za liječenje dijabetesa ovisnog o inzulinu ili dijabetesa melitusa koji nije ovisan o inzulinu.
fluxing with SSC; fluxing with a solution of pepsin; 
ispiranje otopinom soli natrijevog citrata (SSC);
The method according to claim 1, CHARACTERIZED IN THAT the stoichiometric ratio of solid mineral alkaline in powder form to concentrated mineral acid is more than 10:1, preferably more than 15:1, more preferably more than 20:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je stehiometrijski omjer krute mineralne lužine u praškastom obliku i koncentrirane mineralne kiseline veći od 10: 1, poželjno više od 15:1, poželjnije više od 20:1.
The inner part may comprise indentations along a circumference for receiving corresponding protrusions provided on the outer parts, so as to provide a click-on attachment therebetween. 
Unutarnji dio može imati nazubljenja duž oboda radi prihvaćanja odgovarajućih izbočenja koja se nalaze na vanjskim dijelovima, tako da se između njih osigura pričvršćenje utiskivanjem.
The total thickness of the covering layers 7 and 8 may be in the range of 20-30 mm, preferably 22-25 mm. 
Ukupna debljina pokrovnih slojeva 7 i 8 može se nalaziti u rasponu od 20-30 mm, po mogućnosti 22-25 mm.
medical disorders that involve excessive bone loss; 
(a) medicinski poremećaji koji uključuju prekomjerni gubitak kostiju;
Tablets obtainable by the process according to claim 12. 
Tablete, naznačene time što ih se može načiniti postupkom u skladu s patentnim zahtjevom 12. t>&
A mixture of trifluoroacetyl glatiramer acetate, wherein the mixture has a desired average molecular weight, no more than 0.1% brominated tyrosine and less than 1000 ppm metal ion impurities. 
Trifluoracetil glatiramer acetat, naznačen time, da nema više od 0,1% bromiranog tirozina i da ima manje od 1000 ppm nečistoća metalnim ionima,
The method of claim 1, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide consisting of SEQ ID NO: 6. 
Antitijelo specifično protiv kompleksa MHC/peptid MHC-a s peptidom koji se sastoji od SEQ ID No. 22. Komplet koji se sastoji od:
A wheel construction according to claim 4 characterised in that the first and second concave surfaces (41, 42), and the convex formation (44) between the first and second curved surfaces (41, 42) are each of a local respectively internal and external, radius of 18mm. 
Konstrukcija kotača u skladu s patentnim zahtjevom 4, naznačena time da su primarne i sekundarne konkavne površine (41, 42) i konveksna formacija (44) između primarnih i sekundarnih zakrivljenih površina (41, 42) svaka lokalnog, odnosno unutarnjeg i vanjskog polumjera od 18 mm.
A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, for use in a method of treating Sjoegren's syndrome. 
Spoj prema bilo kojem od zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku tretmana Sjogrenovog sindroma.
Example 1.9: Determination of the degree of denaturation 
Broj objave europskog patenta:
Method according to claim 7, wherein the acid is methane sulphonic acid. 
Postupak prema zahtjevu 7, naznačen time da kiselina je metan sulfonska kiselina,
Accordingly, the compounds of the present invention are useful as an active ingredient for the preparation of a medicament, which enables preventive and/or therapeutic treatment of a disease caused by abnormal GSK3B activity and more particularly of neurodegenerative diseases such as Alzheimer's disease. 
Prema tome, spojevi prema ovom izumu su korisni kao aktivni sastojak u pripravi lijeka koji omogućuje preventivno i/ili terapijsko liječenje bolesti uzrokovanih abnormalnom aktivnošću GSK3$, specifičnije neurodegenerativnih bolesti, poput Alzheimerove bolesti.
The composition of any one of claims 1-3, wherein the sorbitol and natural gum are in a weight ratio of at least 1.4:1. 
Kompozicija prema bilo kojem od zahtjeva 1-3, pri čemu su sorbitol i prirodna guma u težinskom odnosu najmanje od 14:1.
administering a compound which stimulates functionality of the receptor in step (b) to a mammal; and determining whether the compound increases a blood GLP-1 level in the mammal; wherein the ability of the test compound to increase a blood GLP-1 level in the mammal is indicative of the test compound being a GLP-1 secretagogue or a compound useful for treating or preventing a condition ameliorated by increasing a blood GLP-1 level. 
Uporaba u skladu sa zahtjevom 19, naznačena time, da navedeni postupak nadalje obuhvaća korak: (c) određivanja nivoa GLP-1 u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen spoj koji stimulira funkcionalnost receptora iz koraka (b); pri čemu je sposobnost test spoja da poveća nivo GLP-1 u krvi u sisavcu nadalje indikativna da je test spoj GLP-1 sekretogog.
An isolated antibody or fragment thereof that is capable of binding to a complex comprising B-Klotho and FGFR1c and induces FGF21-mediated signaling, wherein said isolated antibody or fragment thereof comprises an amino acid sequence 90% identical to SEQ ID NO: 14 and comprises an amino acid sequence 90% identical to SEQ ID NO: 32 for use in therapy. 
Izolirano antitijelo ili njegov fragment koje je sposobno za vezanje za kompleks koji sadrži B-Klotho i FGFR1c i inducira FGF21-posredovani prijenos signala, pri čemu navedeno izolirano antitijelo ili njegov fragment sadrži aminokiselinsku sekvencu 90% identičnu sa SEQ ID NO: 14 i sadrži aminokiselinsku sekvencu 90% identičnu sa SEQ ID NO: 32.
It is also advantageous if the plate-shaped composite structure is brought back to normal pressure again after the groove structures 4 have been filled with the filling medium, and if solidification of the filling medium, which is initially liquid, occurs under normal pressure. 
Kad se brazdaste strukture 4 napune s punilom, tada je također korisno da se pločastu kompozitnu strukturu dovede ponovno natrag pod normalan tlak i da se skrućivanje punila, koje je na početku tekuće, odvija pod normalnim tlakom.
The compound according to claim 1, wherein both Ra and Ra' together are an oxo (=O) group. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što su i Ra i Ra′ zajedno skupina okso (=O).
Method according to any one of the preceding claims, characterized in that prior to 2-((1-methylpropyl)amino)ethanol addition, said suspension has a temperature of between 5 and 100°C, preferably of between 35 and 85°C, and more preferably of between 45 and 75°C. Method according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 1000 to 5000 mg, and preferably of 1300 to 2000 mg, per liter of the aqueous phase of said suspension. 
10. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je prije dodavanja 2-((1- metilpropil)amino)etanola, navedena suspenzija temperature između 5 1 100%, poželjno između 35 1 85"C, poželjnije između 45 i 75%C. 11.Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu suspenziju u količini od 1000 do 5000 mg, poželjnije od 1300 do 2000 mg, po litri vodene faze navedene suspenzije.
adjusting the solution resulting from step (iii) to a protein concentration of about 5 to 7% and a pH value of about 5.5 to 7; and 
(iv) podešavanje otopine dobivene u koraku (iii) do koncentracije proteina od 5 do 7% i pH vrijednosti od 5.5 do
Aqueous or lyophilised material can be packaged into containers (e.g. 
Vodeni ili liofilizirani materijal se može pakirati u spremnike (na pr.
The process according to the invention and the veneer being obtained according to the invention have a series of particular advantages. 
Postupak koji je u skladu s ovim izumom i furnir koji je dobiven u skladu s ovim izumom imaju niz posebnih prednosti.
A fluid distribution system (1000a) according to claim 13, said fluid distribution system (1000a) being arranged to supply fluid to a load, said fluid distribution system comprising: 
Sustav (1000a) za distribuciju fluida prema zahtjevu 13, pri čemu je navedeni Sustav (10004) za distribuciju fluida prilagođen za napajanje opterećenja fluidom, navedeni Sustav za distribuciju fluida sadrži:
that it comprises, viewed in cross-section, an elastically bendable leg; 
- sadrži, gledano u poprečnom presjeku, elastičnu savitljivu nožicu;
The flowable composition of claim 1, wherein the bioactive agent, a metabolite, or a prodrug thereof, comprises a hormone, an immunomodulator, an immunosuppressant, an antibiotic, a cytostatic, a diuretic, a gastrointestinal agent, a cardiovascular agent, a neuropharmaceutical, or a combination thereof. 
Tekući pripravak prema bilo kojem zahtjevu od 1-9, naznačen time da je za uporabu u farmaceutskoj formulaciji, poželjno pri čemu farmaceutska formulacija sadrži hormon, imunomodulacijsko sredstvo, imunosupresijsko sredstvo, = antibiotik, = citostatik, - diuretik, = gastrointestinalno - sredstvo, = kardiovaskularno = sredstvo, ili neurofarmaceutsko sredstvo, ili bilo koju njihovu kombinaciju.
The compound of claim 1, wherein the compound is selected from the group consisting of: and or a pharmaceutically acceptable salt of any of the foregoing. 
Spoj prema zahtjevu 1, naznačen time, što je spoj odabran 1z skupine koja se sastoji od: HR P20181871 T1 0.
% of the total weight of the core particles, the substantially water insoluble particles and water soluble and/or water swellable material particles in the mixing step. 
% ukupne težine čestica jezgre, potpuno u vodi netopivih čestica i u vodi topivih čestica koje su takođe bubre u vodi, kada se pomiješaju.
Preferably, the material is stored below the freezing point, preferably at −18° C. or lower, more preferably at −80° C. or lower with or without previous preservation. 
Metoda prema zahtjevu 17 ili 18, pri čemu se materijal pohranjuje na temperaturi ispod točke smrzavanja, poželjno na -18%C ili niže, još poželjnije na -80%C ili niže, uz prethodno konzerviranje ili bez njega.
reacting a compound of formula (4) with vanillin by a Stobbe condensation reaction, followed by an esterification reaction to prepare the compound of formula (5) 
(a) dovođenja u reakciju spoja formule (4) s vanilijom putem Stobbe-ove reakcije kondenzacije, nakon čega slijedi reakcija esterifikacije u svrhu dobivanja spoja formule (5) 10
The immunoresponsive cell of claim 4, wherein the antigen is selected from the group consisting of prostate-specific membrane antigen (PSMA), Carcinoembryonic Antigen (CEA), IL13Ralpha, her-2, CD19, NY-ESO-1, HIV-1 Gag, Lewis Y, Mart-1, gp100, tyrosinase, WT-1, hTERT, and mesothelin. 
T-stanica za uporabu prema zahtjevu 19 ili farmaceutski pripravak za uporabu prema zahtjevu 20 ili 21, naznačen time da: neoplazija je odabrana iz skupine koju čine rak prostate, rak debelog crijeva, raka dojke, i glioblastom; i/ili tumorski antigen je odabran iz skupine koju čine membranski antigen specifičan za prostatu (PSMA), CD19, NY-ESO-1, WT-1, hTERT, i mezotelin.
The residue was diluted with ethyl acetate, washed with water and brine, dried over anhydrous magnesium sulfate and concentrated. 
Ostatak je razrijeđen etil acetatom, ispran vodom i slanom otopinom, sušen preko bezvodog magnezij sulfata 1 koncentriran.
In an embodiment of the invention there is provided a mushroom production process comprising the step of transferring the heated liquid to a buffer tank prior to delivery to the radiator element. 
Postupak sukladno Zahtjevu 6 koji sadrži korak prijenosa zagrijane tekućine u sabirni spremnik (79), prije isporuke u element za zagrijavanje (15).
the Crystal Violet is approximately 80% pure or greater; and the particle contrast agent composition further comprises Proclin 300. 
Crystal Violet je približno 80% čista 1li više; i pripravak kontrastnog sredstva za čestice dodatno sadrži Proclin 300.
The formulation of paragraph 1 wherein the buffering agent is citrate and the pH is about 7.3. 
Formulacija prema zahtjevu 1, naznačena time da je pufer otopina citrata i pH je oko 7.3.
Also within the scope of the present disclosure are pharmaceutical formulations that include any of the aforementioned compositions in addition to a pharmaceutically acceptable carrier or diluent. Pharmaceutical formulations of the present disclosure will include at least one therapeutic agent. 
Farmaceutska formulacija koja uključuje spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4 ili spoj u skladu s patentnim zahtjevom 5, farmaceutski prihvatljiv nosač ili razrjeđivač i najmanje jedan terapijski agens.
The nonwoven fabric of claim 14, wherein the semi-crystalline polymer of the matrix and binder filaments has a degree of crystallinity of at least 95%. 
Netkano predivo prema bilo kojem od zahtjeva 12-14 i 17-20, naznačeno time, da polukristalni polimer od vlakana ima stupanj kristalnosti od najmanje 50%.
keeping the said viable biological material at the hydrostatic pressure for a predetermined time period; 
držanje navedenog biološkog materijala na hidrostatskom tlaku kroz vremensko razdoblje između 10 sekundi i 150 minuta;
The pharmaceutical composition according to claim 6, wherein the fusion protein comprises an extracellular CD95 domain or a functional fragment thereof and a human Fc domain or a functional fragment thereof. 
Inhibitor CD95 signalnog puta za uporabu u skladu s patentnim zahtjevom 5, pri čemu fuzijski protein sadrži vanstaničnu domenu ili njen funkcionalni fragment i ljudsku Fc domenu ili njen funkcionalni fragment.
The method of claim 20, wherein said additional anti-hepatitis C virus agent is an inhibitor of hepatitis C virus helicase, polymerase, metalloprotease, or IRES. The pharmaceutical composition of claim 16, further comprising another anti-HCV agent. 
Pripravak u skladu s patentnim zahtjevom 14, naznačen time, da je rečeno dodatno sredstvo protiv virusa hepatitisa C inhibitor helikaze, polimeraze, metaloproteaze ili IRES virusa hepatitis C.
A pharmaceutically acceptable salt of a compound according to Formula I: 
PATENTNI ZAHTJEVI mija s» Spoj prema Formuli I:
Risperidone (0.2 mg/kg) was prepared in distilled water and injected i.p. 
Risperidon (0.2 mg/kg) je bio pripremljen u destiliranoj vodi 1 injiciran i.p.
The layers were separated and the aqueous phase was back-extracted with EtOAc (400 mL). 
Slojevi su odijeljeni i vodena faza je ponovno ekstrahirana s EtOAc (400 mL).
The method as claimed in claim 2 or 3, wherein the paper (2) is a thin raw paper with a weight of about 40 - 50 g/m2. 
Metoda u skladu sa patentnim zahtjevom 2 ili 3, gdje je papir (2) tanak sirov papir sa težinom od oko 40 - 50 g/m2.
before the start of the fermentation or during fermentation, inoculating the biogas producing system with a culture of thermophilic, anaerobic, acetogenic, hydrogen-producing bacterium; 
prije početka fermentacije ili tijekom fermentacije, inokuliranje sustava za proizvodnju bioplina s kulturom termofilne, anaerobne, acetogene bakterije,